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Analytical performance of a new 
automated chemiluminescent 
magnetic immunoassays for soluble 
PD-1, PD-L1, and CTLA-4 in human 
plasma
Megumi Goto1, Kenji Chamoto2, Keiko Higuchi1, Saya Yamashita3, Kenta Noda3, 
Takuya Iino4, Masahiro Miura4, Toshinari Yamasaki5, Osamu ogawa5, Makoto sonobe6, 
Hiroshi Date6, Junzo Hamanishi7, Masaki Mandai7, Yoshimasa tanaka8, Shunsuke Chikuma9, 
Ryusuke Hatae2, Manabu Muto10, Sachiko Minamiguchi11, Nagahiro Minato12 & 
Tasuku Honjo13
Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based 
entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise 
biomarkers for the efficacy are required based on immune properties. In particular, expression levels 
of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to 
evaluate the immune state of individuals. Although quantification of their soluble form leased from 
the membrane will provide quick evaluation of patients’ immune status, available methods such as 
enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity 
and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive 
immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, 
providing high reproducibility. Application of this system to plasma of patients with several types of 
tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those 
of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient 
for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our 
newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 
levels in the clinical practice.
Immune checkpoint molecules are one of the most important regulators in the immune system that main-
tain homeostasis by controlling immune reactions1–3. Among the family of immune checkpoints, cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) are the main players inhib-
iting the activation of T cell-mediated immune responses3. Thus, drugs regulating CTLA-4 and PD-1 function, 
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especially blocking antibodies, are currently available and widely used for cancer treatment worldwide4. However, 
not all patients will benefit from this treatment; thus, identification of biomarkers to predict responders and 
non-responders, and/or potential side effects such as autoimmune-related diseases is urgently required.
Originally, PD-1 was discovered as a T cell apoptosis-associated molecule5. However, the observation that 
PD-1-deficient mice developed autoimmune diseases led to the conclusion that PD-1 is a negative regulator 
of immune responses6. One of the ligand of PD-1, programmed cell death-1 ligand-1 (PD-L1) is ubiquitously 
expressed throughout several tissues of the body, whereas PD-1 is mainly expressed on activated lymphocytes. 
When PD-1 binds to PD-L1, the PD-1 signal suppresses activated T cells through the recruitment of SHP-2, 
which dephosphorylates and inactivates Zap70, a major integrator of antigen receptor-mediated signals7,8. PD-L1 
is aberrantly expressed on macrophage-lineage cells and tumour cells, resulting in the strong suppression of 
tumour-reactive T cells.
CTLA-4 is a member of the immunoglobulin superfamily and is highly homologous to another T cell surface 
receptor, CD28 which is critical for T cell activation9,10. Both CD28 and CTLA-4 bind to CD80 and CD86 on 
antigen-presenting cells. However, CTLA-4 binds to CD80 and CD86 with greater affinity and avidity than CD28, 
thus outcompeting CD28 and inhibiting T cell activation. Thus, CTLA-4 is critical for self-tolerance, attenuating 
autoimmunity and anti-tumour immunity11,12.
Numerous surface molecules assume two forms of expression: cell membrane-bound protein and a soluble 
form that is usually generated by proteolytic cleavage13. Splice variants of PD-1 and CTLA-4, or cleaved PD-1, 
PD-L1, and CTLA-4, have been identified as soluble forms in the blood14–17. Given the extensive involvement of 
these immune-regulating molecules in immune reactions and immune-related diseases, detailed investigations 
of the soluble forms of PD-1, PD-L1, and CTLA-4 can offer insight into new biomarker targets. In particular, high 
serum concentrations of the soluble PD-1 (sPD-1), PD-L1 (sPD-L1), and CTLA-4 (sCTLA-4) have been associ-
ated with several autoimmune diseases (e.g., Graves’ disease, myasthenia gravis, systemic lupus erythematosus, 
type 1 diabetes, systemic sclerosis, coeliac disease, autoimmune pancreatitis, and primary biliary cirrhosis)18–20.
Although the levels of sPD-1, sPD-L1, and sCTLA-4 in serum and/or plasma could serve as biomarkers 
of immune-related diseases, several technological issues have limited their clinical application. For instance, 
enzyme-linked immunosorbent assay (ELISA) is typically used to measure the levels of sPD-1, sPD-L1, and 
sCTLA-4, but is known to suffer from poor precision and reproducibility due to the manual procedures of exper-
iments21,22. To overcome these limitations, we developed an automated measurement system for sPD-1, sPD-L1, 
and sCTLA-4 based on a chemiluminescent enzyme immunoassay (HISCL system). Overall, our developed 
method can offer a new tool for the accurate measurement of sPD-1, sPD-L1, and sCTLA-4 in clinical settings, 
and allow for further identification of biomarkers of immune responses.
Results
Standard curve. We chose the best combination of two antibodies for PD-1, PD-L1 and CTLA-4 to obtain 
the highest intensity of chemiluminescent values using HISCL as described in Materials and Methods. These 
sPD-1, sPD-L1, and sCTLA-4 detection assays were standardized using recombinant human PD-1, PD-L1, and 
CTLA-4. Chemiluminescent signals are reportable as relative light units and directly correlate with the amount of 
PD-1, PD-L1, and CTLA-4. Concentrations of PD-1, PD-L1 and CTLA-4 were then determined by interpolation 
from an unweighted four-parameter standard curve obtained by serially diluted calibrators of the recombinant 
proteins (Fig. 1).
Sensitivity. The limit of blanks (LoBs) in these assays for sPD-1, sPD-L1, and sCTLA-4 detection were calcu-
lated with the measurements of 60 zero standards. The LoBs for sPD-1, sPD-L1, and sCTLA-4 were 1.04 pg/mL, 
0.00 pg/mL, and 0.11 pg/mL, respectively. The limit of detections (LoDs) and limit of quantitations (LoQs) were 
tested using five samples with different concentrations. LoDs of sPD-1, PD-L1, and sCTLA-4 were 3.92 pg/mL, 
Figure 1. Relationship between relative photon counts and sPD-1 (a), sPD-L1 (b), and sCTLA-4 (c) levels. 
Serial dilutions of His-tagged PD-1, PD-L1, and CTLA-4 were analyzed and fit into a four-parameter logistic 
regression model.
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6.79 pg/mL, and 0.39 pg/mL; and LoQs were 10.0 pg/mL, 25.0 pg/mL, and 1.0 pg/mL, respectively, based on the 
criterion of a 20% coefficient of variation (CV).
Reproducibility. Control samples with high, mid, and low concentrations were used to evaluate assays for 
reproducibility during the validation runs. The range of CV (%) from the samples prepared from low to high con-
centrations for sPD-1, sPD-L1, and sCTLA-4 assays was <2.7%, 3.7–5.8%, and 2.0–10.9%, respectively (Table 1).
Interference. Interference of common blood components was assessed by adding interfering substances into 
plasma samples. As shown in Table 2, the changes between samples with and without typical interfering sub-
stances in plasma were minor or negligible in the physiological concentration (less than 5% change in sPD-1, 
sPD-L1, and sCTLA-4 concentrations).
Dilution linearity. The dilution linearity of this immune assay system was assessed by measuring the five 
points with different concentrations obtained by diluting the same specimens five times. Specimen dilution anal-
ysis yielded linear results across the dynamic range of the assay. The average correlation between observed and 
expected values of sPD-1, sPD-L1, and sCTLA-4 were >0.99. The sPD-1, sPD-L1, and sCTLA-4 assays were all 
found to be linear between 0.0 and 5277.4, 5289.1, and 5090.8 pg/mL, respectively. The linear relationships with 
slopes corresponded to 1.025 ± 0.0, 0.926 ± 0.0, and 0.960 ± 0.02, respectively (Fig. 2).
Spike recovery. The mean (range) recovery of sPD-1, sPD-L1, and sCTLA-4 calculated by spiking recom-
binant PD-1, PD-L1, and CTLA-4 protein into ten endogenous plasma specimens of healthy donors were 107% 
(102–114%), 103% (96–117%), and 98% (92–104%) for 100 pg/mL (L in Table 3); 108% (101–112%), 94% (84–
109%), and 98% (92–104%) for 250 pg/mL (M in Table 3); and 107% (101–111%), 98% (95–107%), and 100% 
(93–105%) for 1000 pg/mL (H in Table 3).
Specificity. To evaluate the specificity of the assay system, other soluble homologous proteins in the same 
superfamily (PD-1, PD-L1, CTLA-4, B7-1, B7-2, B7-H2, B7-H3, B7-H4, CD28, and PD-L2) were measured 
and compared with the values of sPD-1, sPD-L1, and sCTLA-4. Our assay system detected sPD-1, sPD-L1, and 
sCTLA-4 with less than 0.05% differences when the same molecular concentration of other homologous proteins 
was measured (Fig. 3).
Application of the automated HISCL system to the detection of plasma sPD-1, sPD-L1, and 
sCTLA-4 in cancer patients and healthy controls. As shown in Fig. 4, the sPD-1 level was found to be 
significantly higher in plasma samples from patients with non-small cell lung cancer (NSCLC), renal cell carci-
noma (RCC), ovarian cancer (OVC), Multiple Myeloma (MM), and acute myeloid leukaemia (AML) than that 
detected in healthy donors. The sPD-L1 level was significantly higher in samples from patients with NSCLC, MM, 
and AML than that in healthy donors. Similarly, the sCTLA-4 level was significantly higher in plasma samples 
from patients with NSCLC, melanoma, MM, and AML than in samples from healthy donors. These data indicate 
Levela
sPD-1 sPD-L1 sCTLA-4
L M H L M H L M H
n (Individual) 120 120 120 120 120 120 120 120 120
Mean (pg/mL) 164.8 1003.8 4628.3 210.4 1098.7 5237.4 1.2 1032.1 5574.2
Within-day
CV(%) 2.5 3.0 3.3 5.8 2.3 1.6 12.6 3.5 4.4
SD 4.8 36.7 185.9 13.3 21.9 65.8 0.1 37.4 218.2
Between-day
CV(%) 2.1 2.3 1.9 4.1 2.5 2.0 3.2 1.7 1.9
SD 3.5 22.8 87.9 8.6 26.9 104.1 0.1 17.7 103.7
Overall
CV(%) 2.7 2.7 2.7 5.8 3.7 3.7 10.9 3.5 2.0
SD 4.5 26.9 124.3 12.2 41.2 194.1 0.1 36.4 10.9
Table 1. Twenty-day assay precision evaluation. aL, M, and H indicate low, middle, and high concentration 
controls, respectively. SD, standard deviation; CV, coefficient of variation.
Interfering substances Concentrations
Mean % difference in concentration
sPD-1 sPD-L1 sCTLA-4
Chyle 1660 FTU −1.2 1.3 −2.6
Hemoglobin 4900 mg/L 1.4 1.8 −0.6
Free bilirubin 200 mg/L 1.5 −1.4 −3.1
Ditauro-bilirubin 200 mg/L 0.0 0.0 −0.4
Rheumatoid factor 500 IU/mL −1.4 1.4 −1.3
EDTA-2Na 5000 ug/mL −0.2 0.3 −3.9
Table 2. Interference testing with chyle, hemoglobin, bilirubin, rheumatoid factor, and EDTA- 2Na.
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that sPD-1, sPD-L1, and sCTLA-4 levels in plasma differ according to the tumour type, and confirm the elevated 
immune reactions in cancer patients.
Tumour type-dependent regulation of plasma sPD-1, sPD-L1, and sCTLA-4 levels. In contrast 
to our expectation, there were no significant differences in the plasma levels of sPD-1, sPD-L1, and sCTLA-4 
Figure 2. Dilution linearity of HISCL sPD-1 (a), sPD-L1 (b), and sCTLA-4 (c) assays using serially diluted 
samples. Human plasma spiked with recombinant PD-1/PD-L1/CTLA-4 was diluted with HISCL dilution buffer.
Spike recovery sPD-1 sPD-L1 sCTLA-4
Levela L M H L M H L M H
n (Individual) 10 10 10 10 10 10 10 10 10
spike conc. (pg/
mL) 100.7 248.2 962.2 89.8 235.6 938.9 96.2 237.1 949.5
recovery (%) 107.1 108.0 107.9 103.2 93.9 98.1 98.5 98.3 100.3
Table 3. Spike recovery testing. Ten normal human plasma specimens were spiked at three levels of 
concentration with recombinant PD-1, PD-L1 and CTLA-4. aL, M, and H indicate low, middle, and high 
concentration controls, respectively.
Figure 3. Specificity of HISCL sPD-1, sPD-L1, and sCTLA-4 immunoassays. PD-1, PD-L1, CTLA-4, and other 
immune checkpoint molecules (B7-1, B7-2, PD-L2, B7-H2, B7-H3, B7-H4, and CD28) were diluted to 10 nM 
each and detected by the HISCL PD-1 (a), PD-L1 (b), and CTLA-4 (c) immunoassays.
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before and after the surgery in NSCLC and OVC patients; however, significant differences in sPD-1 and sPD-L1 
levels were detected in RCC patients (Fig. 5a–c). Moreover, compared partial with complete in RCC patients 
that received nephrectomy, the results showed a greater difference in sPD-1 and sPD-L1 levels at before and after 
surgery (Fig. 5d,e).
Discussion
Currently approved predictive biomarkers for the clinical responses to PD-1 blockade cancer immunotherapy are 
PD-L1 expression on tumours and the tumour mutation burden23,24. However, these tumour-derived biomarkers 
are not very reliable for accurate prediction. Since the immune response is controlled by the properties of both the 
tumour and the immune system, biomarkers that reflect immune properties are needed. Although PD-1, PD-L1, 
and CTLA-4 are known as critical immune checkpoint-associated molecules, measuring their expression levels 
in each tissue are quite difficult. Thus, it would be ideal to reliably measure sPD-1, sPD-L1, and sCTLA-4 levels 
in the blood, since the soluble forms of these three molecules are known to be cleaved from the cell surface and 
reflect total expression levels in the body. However, available detection systems for sPD-1, sPD-L1, and sCTLA-4 
are relatively immature. Thus, we used the automated immunochemistry analyser HISCL, which is based on 
chemiluminescent magnetic immunoassay technology, to develop a rapid method for the detection of sPD-1, 
sPD-L1, and sCTLA-4 with good precision, reproducibility, and high sensitivity.
HISCL is widely used for in vitro diagnostics (IVD) in several diseases such as hepatitis, infectious diseases, 
cardiac disease, cancer, sepsis, and atopic dermatitis25–29. The main advantages of HISCL over ELISA are as fol-
lows: (1) due to the liquid-liquid reaction base at 42 °C of the highly-reactive substrate, the reaction is very rapid 
(17 min) and highly sensitive; (2) the larger amounts of antibodies and substrates in liquids provide more capacity 
for the reaction, expanding the dynamic range from the pico- to milligram scale; and (3) all processes are fully 
automated, resulting in high reproducibility. These three conditions are essential for clinical use, especially con-
sidering the necessity of sharing cut-off values between different facilities.
Since tumour tissues are the main site of the immune responses, activated T cells expressing PD-1 and CTLA-4 
are trafficked into tumour tissues. Thus, PD-L1 expression in tumour cells is one of the important predictive 
Figure 4. Levels of sPD-1 (a), sPD-L1 (b), and sCTLA-4 (c) in plasma samples from healthy donors and 
tumour patients. Healthy, n = 50; NSCLC patients, n = 35; RCC patients, n = 33; OVC patients, n = 17; 
melanoma patients, n = 15; MM patients, n = 18; AML patients, n = 17. The Mann-Whitney U test was used for 
comparisons between healthy donor and each tumor patients. One asterisk (*) indicates p-value smaller than 
0.05 (p < 0.05). Two asterisks (**) indicate p-value smaller than 0.01 (p < 0.01).
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biomarkers for clinical responses in the PD-1 blockade cancer immunotherapy for NSCLC. In this context, we 
compared the plasma concentrations of sPD-1, sPD-L1, and sCTLA-4 between healthy donors and tumour bear-
ing patients. It is demonstrated that the plasma concentrations of sPD-1, sPD-L1, and/or sCTLA-4 were higher 
than those of healthy donors, with some differences according to tumour types, implying that anti-tumour immu-
nity has launched in tumour bearing patients. Although sPD-1 is mainly derived from T and B cells, sCTLA-4 
exclusively from T cells, and sPD-L1 from various organs3, it is difficult to define the specific cells in each organ 
that release these soluble factors. To investigate the impact of cancer tissues for the plasma levels of the three 
markers, we compared them before and after the surgical removal of tumour tissues in patients with early stage 
of NSCLC, OVC, and RCC. Our results confirmed that the concentrations of sPD-1, sPD-L1, and sCTLA-4 are 
likely more associated with immune reactions probably in the lymphoid organs rather than in the tumour tissues 
of patients, as there were no differences in these levels before and after surgery except RCC patients. In RCC 
patients, the increment rate of sPD-1 and sPD-L1 after complete removal of the kidney were greater than that 
observed after partial removal, suggesting that sPD-1 and sPD-L1 can be partially eliminated by the kidney. Thus, 
it is likely that the kidney is one of the main sites for the regulation of sPD-1 and sPD-L1 levels in the blood.
Figure 5. Concentrations of sPD-1, sPD-L1, and sCTLA-4 in plasma from NSCLC (a), OVC (b), and RCC (c) 
patients before/after surgery. Levels of sPD-1, sPD-L1, and sCTLA-4 were measured from the patients prior to 
undergoing surgery and at the 4-week post-surgical visit to the hospital. Concentrations of sPD-1 (d) and sPD-
L1 (e) in plasma from RCC patients that received partial or complete nephrectomy, respectively. Differences 
between before and after the surgery groups were assessed by Student t-test.
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In summary, we established rapid and sensitive assay systems for sPD-1, sPD-L1, and sCTLA-4 with a wide 
detection rage. The systems are fully automated, thereby providing high reproducibility. The important point 
for clinical application is determination of cut off values. Therefore, obtaining absolute values without variation 
between different facilities is critical for biomarker studies. Our established method meets this requirement. We 
have planned clinical studies to stratify the cancer patients treated by immune checkpoint inhibitors  based on 
these biomaekers. Considering the importance of immune checkpoints and accumulating evidence of cancer 
immunotherapy, our novel systems can provide new opportunities to identify biomarkers of cancer immunother-
apy and other immune-related diseases. This method would be useful to stratify the patients for “personalized” 
medicine.
Materials and Methods
Human samples. Plasma in di-sodium/-potassium dihydrogen ethylenediaminetetraacetic acid (EDTA) 
tubes from healthy donors or patients with different tumour types [NSCLC (stage III and IV), RCC (stage III, IV 
and recurrent), OVC (stage II–IV), melanoma, MM, and AML] were purchased from ProMedDx, LCC (Norton, 
MA, USA). We further assessed the changes of sPD-1, sPD-L1, and sCTLA-4 concentrations in the plasma of 
cancer patients [NSCLC (stage I, II), RCC (stage I, III), and OVC (stage I–IV)] enrolled from our institute. All 
subjects signed an informed consent form, and all protocols were approved by the Kyoto University Institutional 
Review Board. All methods were performed in accordance with the relevant guidelines and regulations.
Assay description. Antibodies using assay system were conjugated. Anti-PD-1 antibody (MIH4, Thermo 
Fisher Scientific MA, USA), anti-PD-L1 antibody (27A2)30 and anti-CTLA-4 antibody (14D3, Thermo Fisher 
Scientific) were biotinylated. And anti-PD-1 antibody (PD1.3.1.3, Miltenyi Biotec, Bergisch Gladbach, Germany), 
anti-PD-L1 antibody (9L814, US Biological, MA, USA), and anti-CTLA-4 antibody (BNI3, TONBO Biosciences, 
CA, USA) were conjugated to alkaline phosphatase.
sPD-1, sPD-L1, and sCTLA-4 detection assays were standardized using commercially available purified 
recombinant human PD-1, PD-L1, and CTLA-4 with a C-terminal His-tag (Sino Biological Inc., Beijing, China).
A two-step monoclonal antibody sandwich system was used to quantitatively determine the concentrations 
of sPD-1, sPD-L1, and sCTLA-4 in human plasma using immunoassay reagents developed based on the HISCL-
800 system (Sysmex, Hyogo, Japan). In the HISCL system, soluble immune checkpoint molecules were cap-
tured by each specific biotinylated antibody, and the bound products were incubated with alkaline phosphatase 
(ALP) conjugated antibodies (ALP-anti-PD-1, ALP-anti-PD-L1, ALP-anti-CTLA-4). Two reagent packs (sPD-1, 
sPD-L1, and sCTLA-4 detection pack and a chemiluminescence substrate pack) were loaded in the HISCL-800 
system. The detection pack comprised three reagents: a capture antibody buffer solution (R1), a streptavidin mag-
netic beads solution (R2), and an ALP-antibody solution (R3). The chemiluminescence substrate reagent pack 
contained a dilution buffer solution (R4) and CDP-Star substrate solution (R5).
Plasma samples (20 μL) were diluted to 50 μL with R1 and then mixed with R2 (30 μL). After the binding 
reaction, bound/free (B/F) separation was performed. R3 (100 μL) was added to the obtained sample and mixed 
well. Subsequently, after B/F separation, and mixed well with R4 (50 μL) and R5 (100 μL) before reading the fluo-
rescence signal. The chemiluminescent intensity was acquired within a period of 17 min following the operation 
described above. The reaction chamber was maintained at 42 °C throughout the procedure.
Sensitivity. The LoB, LoD, and LoQ values were calculated according to the Clinical Laboratory Standards 
Institute (CLSI) EP17-A2 guideline31. The LoB was analysed using a zero calibrator matrix. The LoD and LoQ 
values were evaluated using five points with different concentrations using recombinant human PD-1, PD-L1, 
and CTLA-4 diluted with calibration buffer. Values were determined by triplicate samples twice with two different 
reagent lots. Measurements were repeated three times on three different days (n = 18 for each point).
Reproducibility. Assay precision was evaluated according to the CLSI EP05-A3 guideline following a 
20 × 2 × 2 experimental design32. We pooled normal human plasma samples as a low-concentration control. 
Subsequently, middle- and high-concentration panels were prepared by adding recombinant proteins to the 
pooled plasma. The panels were run in replicates of six, twice daily with a 2 hours or greater gap between runs. 
The human plasma panel represents the native endogenous sPD-1, sPD-L1, and sCTLA-4 concentrations (for 
low-concentration group). For the middle- and high-concentration groups, recombinant human PD-1, PD-L1, 
and CTLA-4 were spiked into the low-concentration control up to 1188 pg/mL, 538 pg/mL, and 877 pg/mL, 
respectively. For the high-concentration panel, recombinant PD-1, PD-L1, and CTLA-4 proteins were added up 
to 5455 pg/mL, 2654 pg/mL, and 4789 pg/mL, respectively.
Interfering substances. Potential interference materials were added to the plasma pool of healthy donors 
up to the following concentrations: chyle (0–1660 FTU), haemoglobin (0–4900 mg/L), free-form bilirubin 
(0–200 mg/L), conjugated-form bilirubin (0–200 mg/L), rheumatoid factor (RF; 0–500 IU/mL), and EDTA-2Na 
(0–5000 μg/mL). The free-form and conjugated-forms of bilirubin, haemoglobin, lipids, and RF were obtained 
from interference Check A Plus and Interference Check RF (Sysmex, Hyogo, Japan).
Dilution linearity. Dilution linearity was assessed according to CLSI guideline EP06-A33. Samples of human 
plasma were spiked with recombinant PD-1, PD-L1, and CTLA-4 and then diluted five times with HISCL dilution 
buffer.
Specificity. The specificity of assay system was also determined by other homologous proteins in the same 
superfamily. PD-1, PD-L1, CTLA-4, B7-1, B7-2, B7-H2, B7-H3, B7-H4, CD28, and PD-L2 with a C-terminal 
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His-tag were purchased from Sino Biological. These proteins were prepared 10 nM concentration with calibration 
buffer and measured triplicate by our assay system.
statistical analysis. Statistical analysis was performed using StatFlex v.6.0 software (Artech Co. Ltd., Osaka, 
Japan) and was expressed as Mean, Standard Deviation (SD) and Coefficient of Variation (CV) for each test 
parameter. Linearity was assessed by linear regression analysis. The Mann-Whitney U test was used for compar-
isons between healthy donor and each tumour patients. Differences between before and after the surgery groups 
were assessed by Student t-test, and a P-value < 0.05 was considered to be statistically significant.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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